New research challenges fears about Ozempic weight regain. Cleveland Clinic study of 8,000 patients finds minimal rebound ...

This article was reviewed by Mike Bohl, MD. If you’ve been using a GLP-1 such as semaglutide, then you’ve likely experienced ...

A new study suggests that almost half of people stopping GLP-1 weight-loss drugs may keep the weight off. However, many of ...

After years of fighting over compounded weight loss drugs, Hims & Hers and Novo Nordisk are teaming up to sell Ozempic and ...

Novo Nordisk has multiple weight-loss drugs in various stages of development and approval, according to its R&D pipeline.

Medicare had banned coverage of weight-loss drugs for 23 years, and what happens next isn't as simple as the headlines ...

GLP-1 drugs are driving major weight loss trends, but doctors warn that rapid weight loss may affect nutrition, bone density, heart health, and blood sugar balance.

Hims & Hers Health, Inc. (NYSE: HIMS) today announced a collaboration with Novo Nordisk as part of a new strategy for weight loss care treatments involving GLP-1s, evolving its US offering to match ...